Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02713321 · ClinicalTrials.gov registry record

Impact of Medicaid Health Home on Patients With Diabetes in New York City

A clinical trial of Type 2 Diabetes Mellitus, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
96,759
Enrollment target
1
Study location

NCT02713321 is a study of Type 2 Diabetes Mellitus that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 96,759 participants, above the 1,955-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (4849% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02713321, a study of Type 2 Diabetes Mellitus, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
96,759 participants
Enrollment target
1
Study location

Study Summary

Type 2 diabetes is common in the United States; about 1 in 10 people have the disease. Diabetes can cause devastating health events, such as hospitalizations, kidney failure, blindness, amputation, heart attack, stroke, painful nerve damage (neuropathy), and death. There are many barriers for patients with diabetes that get in the way of controlling risk factors, following recommendations, and getting the care they need from the health system to help prevent these complications; this is especially true for those with other health problems too. Those living in poverty and racial/ethnic minorities are more likely to have complications from diabetes, and less likely to get recommended care from health systems. In order to improve care and outcomes for people with complex medical problems, several states have started the Medicaid Health Home (HH) program, including New York State (NYS) in 2012. This program is for people with two or more chronic health conditions, such as diabetes and heart disease, people with HIV, and people with a serious mental health condition. HHs are meant to manage and coordinate care, by helping health care providers, social service agencies, community-based organizations, and health insurance plans work together. Similar programs have been shown, on a smaller scale, to improve some results for patients with diabetes, such as lab tests indicating level of diabetes control. Studies have not yet looked at how a large program like HHs impacts the way healthcare is delivered and impacts the health events that matter most to patients with diabetes. Also, few studies include stakeholders on the research team, even though they stand to benefit the most from such programs, and have the experience needed as patients, clinicians, advocates, and administrators to guide efforts. The investigators have gathered a research team that includes scientific investigators along with a diverse group of partners, including patients, clinicians, and program administr

Conditions Studied

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 96,759 participants
Start Date 2017-01-24
Est. Completion 2021-08-31

What the Registry Record Tells You About NCT02713321

The ClinicalTrials.gov registry entry for NCT02713321 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 96,759 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,955-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (4849% higher). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.

NCT02713321 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02713321 about?

NCT02713321 is a clinical study titled "Impact of Medicaid Health Home on Patients With Diabetes in New York City". Type 2 diabetes is common in the United States; about 1 in 10 people have the disease. Diabetes can cause devastating health events, such as hospitalizations, kidney failure, blindness, amputation, heart attack, stroke, painful nerve damage (neuropathy), and death. There are many barriers for patien...

What is the current status of trial NCT02713321?

This trial is currently completed. The enrollment target is 96,759 participants. The study started on 2017-01-24. Estimated completion is 2021-08-31.

What conditions does trial NCT02713321 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

Who is sponsoring clinical trial NCT02713321?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02713321 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.